Literature DB >> 32868512

Subarachnoid neurocysticercosis: emerging concepts and treatment.

Theodore E Nash1, Elise M O'Connell.   

Abstract

PURPOSE OF REVIEW: Subarachnoid neurocysticercosis (SUBNCC) is caused by a morphologically unique proliferative form of Taenia solium involving the subarachnoid spaces. Prolonged therapy based upon the pathophysiology of SUBNCC and long-term follow-up have shed light on the course of disease and led to highly improved outcomes. RECENT
FINDINGS: SUBNCC has a prolonged incubation period of between 10 and 25 years characterized by cyst proliferation and growth and invasion of contiguous spaces leading to mass effect (Stage 1). With induction of the host-immune responses, cysts degenerate leading to a predominately inflammatory arachnoiditis (Stage 2) causing hydrocephalus, infarcts, and other inflammatory based neurological manifestations. Inactive disease (Stage 3) may occur naturally but mostly is a result of successful treatment, which generally requires prolonged intensive anthelminthic and antiinflammatory treatments. Cerebral spinal fluid cestode antigen or cestode DNA falling to nondetectable levels predicts effective treatment. Prolonged treatment with extended follow-up has resulted in moderate disability and no mortality. Repeated short intensive 8-14-day courses of treatment are also used, but long-term outcomes and safety using this strategy are not reported.
SUMMARY: SUBNCC gives rise to a chronic arachnoiditis. Its unique ability to proliferate and induce inflammatory responses requires long-term anthelmintic and antiinflammatory medications.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32868512      PMCID: PMC7733161          DOI: 10.1097/QCO.0000000000000669

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.968


  44 in total

1.  Neurocysticercosis in Houston, Texas: an update.

Authors:  Jose A Serpa; Edward A Graviss; Joseph S Kass; A Clinton White
Journal:  Medicine (Baltimore)       Date:  2011-01       Impact factor: 1.889

2.  Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis.

Authors:  F Göngora-Rivera; J L Soto-Hernández; D González Esquivel; H J Cook; C Márquez-Caraveo; R Hernández Dávila; J Santos-Zambrano
Journal:  Neurology       Date:  2005-12-28       Impact factor: 9.910

3.  High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis.

Authors:  D Callacondo; H H Garcia; I Gonzales; D Escalante; T E Nash
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

4.  Human neurocysticercosis: comparison of different diagnostic tests using cerebrospinal fluid.

Authors:  Lorraine Michelet; Agnès Fleury; Edda Sciutto; Eric Kendjo; Gladis Fragoso; Luc Paris; Bernard Bouteille
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

5.  Lacunar syndrome due to neurocysticercosis.

Authors:  F Barinagarrementeria; O H Del Brutto
Journal:  Arch Neurol       Date:  1989-04

6.  Neurocysticercosis: detection of Taenia solium DNA in human cerebrospinal fluid using a semi-nested PCR based on HDP2.

Authors:  M Hernández; L M Gonzalez; A Fleury; B Saenz; R M E Parkhouse; L J S Harrison; T Garate; E Sciutto
Journal:  Ann Trop Med Parasitol       Date:  2008-06

7.  Severe forms of neurocysticercosis: treatment with albendazole.

Authors:  S Agapejev; M D Da Silva; A K Ueda
Journal:  Arq Neuropsiquiatr       Date:  1996-03       Impact factor: 1.420

8.  Next generation sequencing based pathogen analysis in a patient with neurocysticercosis: a case report.

Authors:  Ping Liu; Xing Weng; Jiajia Zhou; Xiaolin Xu; Fangping He; Yue Du; Honglong Wu; Yanping Gong; Guoping Peng
Journal:  BMC Infect Dis       Date:  2018-03-06       Impact factor: 3.090

9.  Extraparenchymal neurocysticercosis: Demographic, clinicoradiological, and inflammatory features.

Authors:  Mariana Marcin Sierra; Mariana Arroyo; May Cadena Torres; Nancy Ramírez Cruz; Fernando García Hernández; Diana Taboada; Ángeles Galicia Martínez; Tzipe Govezensky; Edda Sciutto; Andrea Toledo; Agnès Fleury
Journal:  PLoS Negl Trop Dis       Date:  2017-06-09

10.  Intraventricular Neurocysticercosis: Experience and Long-Term Outcome from a Tertiary Referral Center in the United States.

Authors:  Theodore E Nash; JeanAnne M Ware; Siddhartha Mahanty
Journal:  Am J Trop Med Hyg       Date:  2018-04-19       Impact factor: 2.345

View more
  2 in total

Review 1.  Spinal arachnoiditis and syringomyelia: Review of literature with emphasis on postinfectious inflammation and treatment.

Authors:  Syed Faisal Nadeem; Ahmer Nasir Baig; Qurat Ul Ain Tariq; Muhammad Shahzad Shamim
Journal:  Surg Neurol Int       Date:  2022-07-15

Review 2.  Neurocysticercosis. A frequent cause of seizures, epilepsy, and other neurological morbidity in most of the world.

Authors:  J Bustos; I Gonzales; H Saavedra; S Handali; H H Garcia
Journal:  J Neurol Sci       Date:  2021-06-17       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.